BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Quarterly Earnings Results, Beats Expectations By $0.25 EPS

Posted by Brenda Bartman on Aug 7th, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) released its earnings results on Thursday. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.25, FiscalAI reports. The business had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 6.50% and a net margin of 8.29%.The business’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same period last year, the company earned $1.44 earnings per share. BioMarin Pharmaceutical updated its FY 2026 guidance to 4.900-5.100 EPS.

Here are the key takeaways from BioMarin Pharmaceutical’s conference call:

Second-quarter revenue rose 20% year over year to nearly $1 billion, supported by broad-based demand and the Amicus contribution. BioMarin raised its full-year revenue, VOXZOGO revenue, and non-GAAP EPS guidance.
The Amicus integration is progressing ahead of expectations, with projected peak revenue of $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI/OPFOLDA, plus approximately $220 million in annual cost synergies by 2028. Management expects meaningful EPS accretion beginning in 2027 and deleveraging roughly one year earlier than previously anticipated.
VOXZOGO revenue increased 14% year over year, while treated children grew more than 20% globally despite a new U.S. competitor. Approximately 90% of U.S. patients remained on therapy, and BioMarin submitted a supplemental application for hypochondroplasia approval, potentially supporting a 2027 launch.
BioMarin added BMN 820, an oral CCR2 inhibitor in Phase III development for focal segmental glomerulosclerosis, to its late-stage pipeline. The company also expects to pursue additional clinical-stage business-development opportunities over the next 12 to 18 months.
Acquisition financing is increasing annual interest expense by approximately $200 million, or $50 million per quarter, while reduced cash balances are lowering interest income. These factors, along with higher operating expenses, contributed to lower year-over-year non-GAAP diluted EPS in the quarter.

BioMarin Pharmaceutical Stock Up 3.8%

NASDAQ BMRN traded up $2.35 during trading on Friday, hitting $63.81. The company’s stock had a trading volume of 4,365,078 shares, compared to its average volume of 2,059,677. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $66.28. The company has a market cap of $12.33 billion, a PE ratio of 46.58, a P/E/G ratio of 0.46 and a beta of 0.24. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20. The business’s 50 day simple moving average is $58.06 and its 200-day simple moving average is $57.01.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

Positive Sentiment: BioMarin reported second-quarter revenue of approximately $990 million, up 20% year over year and above the $932 million consensus estimate. Adjusted EPS of $1.20 also exceeded expectations of roughly $0.95-$0.96, providing a clear earnings catalyst despite being below the $1.44 reported in the prior-year quarter. BioMarin Reports Second Quarter 2026 Financial and Operating Results
Positive Sentiment: The company raised its full-year 2026 non-GAAP EPS outlook to $4.90-$5.10, above the approximately $4.80 analyst consensus. Revenue guidance of about $3.9 billion was maintained around expectations, while stronger growth projections were provided for VOXZOGO. BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
Positive Sentiment: Management said the additions of GALAFOLD and POMBILITI plus OPFOLDA from Amicus, along with expected cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion, and cash flow through the mid-2030s. BioMarin Reports Second Quarter 2026 Financial and Operating Results
Positive Sentiment: Morgan Stanley raised its price target from $119 to $124 and maintained an “overweight” rating, signaling substantial confidence in BioMarin’s growth and earnings outlook. Morgan Stanley analyst action
Neutral Sentiment: HC Wainwright increased its price target from $50 to $60 but retained a “neutral” rating, offering a more cautious view of the stock’s valuation and upside. HC Wainwright analyst action

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on BMRN shares. Royal Bank Of Canada cut their price target on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 7th. Canaccord Genuity Group lowered their price target on shares of BioMarin Pharmaceutical from $116.00 to $111.00 and set a “buy” rating for the company in a research report on Friday, May 22nd. UBS Group restated a “neutral” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 14th. The Goldman Sachs Group started coverage on BioMarin Pharmaceutical in a research report on Monday, May 11th. They set a “neutral” rating and a $69.00 target price on the stock. Finally, Wall Street Zen downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.86.

View Our Latest Research Report on BioMarin Pharmaceutical

Institutional Trading of BioMarin Pharmaceutical

Institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC grew its holdings in shares of BioMarin Pharmaceutical by 159.5% during the fourth quarter. Corient Private Wealth LLC now owns 15,145 shares of the biotechnology company’s stock valued at $900,000 after buying an additional 9,309 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its position in BioMarin Pharmaceutical by 1.4% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 64,069 shares of the biotechnology company’s stock worth $3,808,000 after acquiring an additional 910 shares during the period. EP Wealth Advisors LLC acquired a new position in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $240,000. Krensavage Asset Management LLC raised its stake in shares of BioMarin Pharmaceutical by 29.4% in the fourth quarter. Krensavage Asset Management LLC now owns 524,786 shares of the biotechnology company’s stock worth $31,188,000 after purchasing an additional 119,336 shares during the last quarter. Finally, Mackenzie Financial Corp raised its stake in shares of BioMarin Pharmaceutical by 114.0% in the fourth quarter. Mackenzie Financial Corp now owns 375,067 shares of the biotechnology company’s stock worth $22,082,000 after purchasing an additional 199,840 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

(Get Free Report)

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.